Phenoxybenzamine in prostatic hypertrophy. A double-blind study

Forty-five patients awaiting prostatectomy participated in a double-blind study of phenoxybenzamine 10 mg/day for 5 weeks. Objective measurements of peak urine flow, voided volume, residual urine and frequency of micturition and nocturia showed no significant difference between phenoxybenzamine and placebo. Patients taking phenoxybenzamine had a significantly greater improvement in hesitancy and flow symptoms than those on placebo. Side effects occurred in 47.6% of patients on phenoxybenzamine and 22.2% of those on placebo. In this study phenoxybenzamine 10 mg/day was ineffective in patients with benign prostatic hypertrophy.